GOTEBORG, Sweden, October 2 Calabar AB announced todaythat their Phase II repeated dose study in xerostomia ("dry mouth") patientshas been initiated. Specifically, the drug will be studied in 45 dry mouthpatients between the ages of 20 to 75. The objective of the study is toselect a dose for evaluation in a succeeding Phase III efficacy study.
Xalieve(TM) is a gel containing the cholinesterase inhibitorphysostigmine. It is administered locally in the mouth where physostigminediffuses through the mucosa reaching the minor glands. By inhibitingcholinesterase, acetylcholine accumulates and the elevated concentrationsstimulate the muscarinic receptors in the minor glands, improving salivaproduction. Unlike systemically administered drugs, the local route ofadministration limits adverse events.
"Xalieve(TM) offers a completely new approach in treating dry mouth andwe are very excited about this Phase II study," said Mr. Fredrik Rook, VPBusiness Development of Calabar. "Xerostomia is not getting the attention itdeserves. These patients are experiencing dramatic decrease in quality oflife, such as difficulty in swallowing and speaking, and a burning sensationin the mouth. Xalieve(TM) has the possibility to radically improve the lifeof millions of people suffering from dry mouth."
About Calabar AB:
Calabar is a privately-held company committed to developingpharmaceutical products addressing the significant unmet needs of xerostomia"dry mouth". The company's product Xalieve(TM) is a locally administeredformulation of the cholinesterase inhibitor physostigmine, which has beenshown to effectively increase salivary flow. The company is part of theKarolinska Development AB portfolio. For more information, please visithttp://www.calabar.seContact: VP Business Development, Fredrik Rook, +46-8-524-860-38, firstname.lastname@example.org .
SOURCE Calabar AB